Why is Tyra Biosciences stock plunging today?

Tyra Biosciences shares tumbled 31.1% in pre-market trading to $18.42 following the release of eagerly awaited Phase 2 SURF302 data for oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). The headline complete response (CR) rate came in below the level analysts had considered a minimum for success. The results showed an overall response rate of 79%, but the best overall complete response rate was just 64% at the 60 mg once-daily dose. The trial was intended as a clinical proof-of-concept for selective oral FGFR3 inhibition, and the 60 mg daily dose was selected as the likely candidate for a planned registrational adjuvant development program.

The selloff underscores the wide divergence between the observed CR rate and what investors had built into the stock. Piper Sandler, which maintained an Overweight rating and a $56 price target, had valued the intermediate-risk non-muscle invasive bladder cancer indication as a more than $1 billion market opportunity for dabogratinib. Both Piper Sandler and H.C. Wainwright had publicly set a 70% three-month complete response rate as the threshold for success, so the 64% figure represented a clear disappointment relative to consensus. Safety data, however, were reassuring across the 60 mg and 50 mg dose groups, with the majority of adverse events graded 1–2, no Grade 4–5 events, and no dose reductions or treatment-related discontinuations in the 60 mg arm. Additionally, the shares entered the catalyst event at a rich valuation, having rallied roughly 13% in the previous week alone.

The overall market offered scant relief. In pre-market trading, the S&P 500, Dow Jones, and Nasdaq were all modestly lower as investors remained cautious. The robust August nonfarm payrolls report, which showed a gain of 162,000 jobs—nearly triple forecasts—and an unemployment rate steady at 4.1%, has fueled uncertainty over the Federal Reserve's next policy step. That macro backdrop layered additional pressure onto an already risk-off session for speculative biotechnology stocks.

Together, the complete response miss relative to a widely known analyst yardstick, the rally that had already priced in a successful result, and the cautious broader market set the stage for today's sharp pre-market decline. While the company has designated 60 mg once-daily as the dose for its intended registrational adjuvant trial and management has said it will examine a 70 mg cohort, investors for now are adjusting the stock's valuation to reflect the greater uncertainty surrounding the drug's regulatory and commercial prospects after the efficacy result came in beneath the benchmark.

This article was produced with the assistance of artificial intelligence and was reviewed by an editor. Additional details are available in our Terms and Conditions.